China Salmeterol/Ticasone Market Investigation Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Investigation Report on Chinese Salmeterol/Ticasone Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

According to the analysis, from 2021 to 2025, the sales of Salmeterol/Ticasone in China will have a recovery growth with the improvement of the epidemic situation and normal operation of overall diagnosis and treatment in hospitals.

After the patent for Salmeterol/Ticasone expired, more biosimilar drugs will appear on the market. In China, Respirent Pharmaceuticals Co. Ltd has already submitted an application for Salmeterol/Ticasone in 2021.

Therefore, in the next few years, the market share for Glaxo Wellcome (formerly the wellcome Foundation) and GlaxoSmithKline (France) will gradually shrink. At the same time, with the launch of biosimilar drugs, the price will be further reduced. The price adjustment will reduce the burden on patients, thereby increasing the use and sales of Salmeterol/Ticasone.

Salmeterol/Ticasone is a compound medication used in the regular treatment of asthma and chronic obstructive pulmonary disease (COPD). Its original drug was developed by GlaxoSmithKline.

In 2001, Salmeterol Ticasone powder inhalation was approved to enter the Chinese market, and its indication was chronic obstructive pulmonary disease (COPD), and its trade name was SERETIDE; a new indication for asthma was added in China in 2010. SERETIDE powder inhalation has been covered in the category B medical insurance catalogs of 31 provinces, and by 2020 the manufacturers of Salmeterol/Ticasone in China are Glaxo Wellcome(formerly the welcome Foundation) and GlaxoSmithKline(France).

According to this market research, the sales of Salmeterol/Ticasone have had an increasing trend in the Chinese market from 2016 to 2019. The sales revenue in 2020 was approximately CNY296.77million. However, the sales of Salmeterol/Ticasone in 2020 decreased by 21.59% compared with that in 2019 due to the COVID-19 epidemic. The CAGR for Salmeterol/Ticasone is approximately -3.82% from 2016 to 2020.

Topics Covered:

• The impact of COVID-19 on China's Salmeterol/Ticasone market
• Sales value of China's Salmeterol/Ticasone 2016-2020
• Competitive landscape of China's Salmeterol/Ticasone market
• Prices of Salmeterol/Ticasone in China
• Prices of Salmeterol/Ticasone in China by regions and manufacturers
• Analysis on factors affecting the development of China's Salmeterol/Ticasone market
• Prospect of China's Salmeterol/Ticasone market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Salmeterol/Ticasone

1.1 Indications for Salmeterol/Ticasone

1.2 Development of Salmeterol/Ticasone in China

1.3 Governmental Approval of Salmeterol/Ticasone in China

1.4 The Impact of COVID-19 on Salmeterol/Ticasone sales in China

2 Sales of Salmeterol/Ticasone in China, 2016-2020

2.1 Sales Value of Salmeterol/Ticasone

2.1.1 Overall Sales Value

2.1.2 Sales Value by Regions

2.2 Sales Volume of Salmeterol/Ticasone

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 Sales of Salmeterol/Ticasone by Dosage Form in China, 2016-2020

2.3.1Gas (powder) aerosol

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Salmeterol/Ticasone Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Salmeterol/Ticasone Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Glaxo Wellcome (formerly the wellcome Foundation)

3.2.1 Enterprise Profile

3.2.2 Sales of SERETIDE (Glaxo Wellcome (formerly the wellcome Foundation)'s Salmeterol/Ticasone) in China

3.3 GlaxoSmithKline (France)

3.3.1 Enterprise Profile

3.3.2 Sales of SERETIDE (GlaxoSmithKline (France)) in China

4 Prices of Salmeterol/Ticasone for Different Manufacturers in China, 2020-2021

4.1 Glaxo Wellcome (formerly the wellcome Foundation) (SERETIDE)

4.2 GlaxoSmithKline (France) (SERETIDE)

5 Prospect of Chinese Salmeterol/Ticasone drug Market, 2021-2025

5.1 Influential Factors of Chinese Salmeterol/Ticasone Market Development

5.1.1 The Impact of COVID-19 on Chinese Salmeterol/Ticasone Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

Companies Mentioned

• Glaxo Wellcome
• GlaxoSmithKline
• Respirent Pharmaceuticals Co. Ltd

For more information about this report visit https://www.researchandmarkets.com/r/p4ifuf